ST Pharm Co.Ltd
ST Pharm Co. Ltd., a contract development manufacturing organization, provides products for pharmaceutical and non-pharmaceutical area in South Korea. The company offers chemistry manufacturing control (CMC) services, which includes analytical method development; in-house reference standard testing; analytical method qualification/validation; analytical characterization; and CMC documentation. It… Read more
ST Pharm Co.Ltd (237690) - Net Assets
Latest net assets as of September 2025: ₩555.98 Billion KRW
Based on the latest financial reports, ST Pharm Co.Ltd (237690) has net assets worth ₩555.98 Billion KRW as of September 2025.
Net assets (also known as shareholders' equity or book value) represent the difference between a company's total assets (₩755.49 Billion) and total liabilities (₩199.52 Billion). This figure indicates the residual interest in the assets after deducting liabilities, essentially showing what would remain for shareholders if all assets were liquidated and all debts paid off.
Key Net Assets Metrics
| Metric | Value |
|---|---|
| Current Net Assets | ₩555.98 Billion |
| % of Total Assets | 73.59% |
| Annual Growth Rate | 16.49% |
| 5-Year Change | 70.32% |
| 10-Year Change | N/A |
| Growth Volatility | 45.17 |
ST Pharm Co.Ltd - Net Assets Trend (2015–2024)
This chart illustrates how ST Pharm Co.Ltd's net assets have evolved over time, based on quarterly financial data. Explore and compare other companies by net assets.
Annual Net Assets for ST Pharm Co.Ltd (2015–2024)
The table below shows the annual net assets of ST Pharm Co.Ltd from 2015 to 2024.
| Year | Net Assets | Change |
|---|---|---|
| 2024-12-31 | ₩502.99 Billion | +30.00% |
| 2023-12-31 | ₩386.91 Billion | +14.59% |
| 2022-12-31 | ₩337.63 Billion | +4.54% |
| 2021-12-31 | ₩322.97 Billion | +9.36% |
| 2020-12-31 | ₩295.33 Billion | -1.87% |
| 2019-12-31 | ₩300.96 Billion | -9.23% |
| 2018-12-31 | ₩331.57 Billion | -5.56% |
| 2017-12-31 | ₩351.08 Billion | +12.08% |
| 2016-12-31 | ₩313.24 Billion | +146.01% |
| 2015-12-31 | ₩127.33 Billion | -- |
Equity Component Analysis
This analysis shows how different components contribute to ST Pharm Co.Ltd's total equity over time. Equity components include common stock, retained earnings, additional paid-in capital, and other elements.
Equity Composition Insights
- Retained earnings have grown by 109.7% over the analyzed period, indicating profitable operations and earnings retention.
Current Equity Component Breakdown (December 2024)
| Component | Amount | Percentage |
|---|---|---|
| Retained Earnings | ₩159.44 Billion | 31.69% |
| Common Stock | ₩10.08 Billion | 2.00% |
| Other Components | ₩333.62 Billion | 66.31% |
| Total Equity | ₩503.13 Billion | 100.00% |
ST Pharm Co.Ltd Competitors by Market Cap
The table below lists competitors of ST Pharm Co.Ltd ranked by their market capitalization.
| Company | Market Cap |
|---|---|
|
PDF Solutions Inc
NASDAQ:PDFS
|
$1.05 Billion |
|
Faes Farma SA
MC:FAE
|
$1.05 Billion |
|
Bittium Oyj
HE:BITTI
|
$1.05 Billion |
|
SIMCERE PHARMAC. GRP LTD
F:S2P
|
$1.05 Billion |
|
QUIDELORTHO DL-001
F:QL1A
|
$1.05 Billion |
|
L&T Technology Services Limited
NSE:LTTS
|
$1.05 Billion |
|
Mercialys SA
PA:MERY
|
$1.05 Billion |
|
Deutsche Wohnen AG
LSE:0OBQ
|
$1.05 Billion |
Equity Growth Attribution
This analysis shows how different factors contributed to changes in ST Pharm Co.Ltd's equity between the two most recent reporting periods.
Equity Growth Insights
- From 2023 to 2024, total equity changed from 384,550,358,510 to 503,132,372,460, a change of 118,582,013,950 (30.8%).
- Net income of 34,711,730,620 contributed positively to equity growth.
- Dividend payments of 9,404,387,500 reduced retained earnings.
- Other factors increased equity by 93,274,670,830.
Equity Change Factors (2023 to 2024)
| Factor | Impact | Contribution |
|---|---|---|
| Net Income | ₩34.71 Billion | +6.9% |
| Dividends Paid | ₩9.40 Billion | -1.87% |
| Other Changes | ₩93.27 Billion | +18.54% |
| Total Change | ₩- | 30.84% |
Book Value vs Market Value Analysis
This analysis compares ST Pharm Co.Ltd's book value (net assets) with its market value over time. The relationship between these values can provide insights into investor sentiment and company valuation.
Valuation Insights
- Current price-to-book ratio: 6.14x
- The company is trading at a significant premium to its book value, suggesting the market values its earnings potential, brand, or other intangibles highly.
- The price-to-book ratio has decreased from 9.05x to 6.14x over the analyzed period, indicating reduced market premium.
Historical Price-to-Book Ratios
| Date | Book Value per Share | Market Price | P/B Ratio |
|---|---|---|---|
| 2016-12-31 | ₩16946.43 | ₩153400.00 | x |
| 2017-12-31 | ₩18818.76 | ₩153400.00 | x |
| 2018-12-31 | ₩17772.78 | ₩153400.00 | x |
| 2019-12-31 | ₩16131.97 | ₩153400.00 | x |
| 2020-12-31 | ₩15830.19 | ₩153400.00 | x |
| 2021-12-31 | ₩17171.46 | ₩153400.00 | x |
| 2022-12-31 | ₩17950.76 | ₩153400.00 | x |
| 2023-12-31 | ₩20445.26 | ₩153400.00 | x |
| 2024-12-31 | ₩24965.77 | ₩153400.00 | x |
Capital Efficiency Dashboard
This dashboard shows how efficiently ST Pharm Co.Ltd utilizes its equity to generate returns, including Return on Equity (ROE) and its components based on the DuPont analysis framework.
Capital Efficiency Insights
- Current Return on Equity (ROE): 6.90%
- The company has moderate efficiency in generating returns from equity.
- DuPont Analysis Breakdown:
- • Net Profit Margin: 12.68%
- • Asset Turnover: 0.38x
- • Equity Multiplier: 1.43x
- Recent ROE (6.90%) is above the historical average (6.04%), indicating improving capital efficiency.
Historical Capital Efficiency Metrics
| Year | Return on Equity | Net Profit Margin | Asset Turnover | Equity Multiplier | Economic Value Added |
|---|---|---|---|---|---|
| 2015 | 22.72% | 18.25% | 0.59x | 2.10x | ₩14.10 Billion |
| 2016 | 19.61% | 30.66% | 0.54x | 1.17x | ₩30.10 Billion |
| 2017 | 12.82% | 22.19% | 0.53x | 1.09x | ₩9.89 Billion |
| 2018 | -2.80% | -9.48% | 0.28x | 1.04x | ₩-42.42 Billion |
| 2019 | -6.16% | -19.87% | 0.27x | 1.13x | ₩-48.62 Billion |
| 2020 | -4.11% | -9.79% | 0.28x | 1.51x | ₩-41.68 Billion |
| 2021 | 1.03% | 2.00% | 0.33x | 1.54x | ₩-28.99 Billion |
| 2022 | 5.33% | 7.22% | 0.44x | 1.69x | ₩-15.76 Billion |
| 2023 | 5.09% | 6.87% | 0.42x | 1.76x | ₩-18.87 Billion |
| 2024 | 6.90% | 12.68% | 0.38x | 1.43x | ₩-15.60 Billion |
Industry Comparison
This section compares ST Pharm Co.Ltd's net assets metrics with peer companies in the Pharmaceuticals industry.
Industry Context
- Industry: Pharmaceuticals
- Average net assets among peers: $96,196,506,488
- Average return on equity (ROE) among peers: -9.52%
Peer Company Comparison
| Company | Net Assets | Return on Equity | Debt-to-Equity | Market Cap |
|---|---|---|---|---|
| ST Pharm Co.Ltd (237690) | ₩555.98 Billion | 22.72% | 0.36x | $1.05 Billion |
| Sam Chun Dang Pharm. Co. Ltd (000250) | $114.32 Billion | 10.17% | 0.61x | $3.69 Billion |
| DongKoo Bio&Pharma Co. Ltd (006620) | $94.65 Billion | 9.66% | 0.53x | $57.77 Million |
| NatureCell Co.Ltd (007390) | $34.02 Billion | -9.48% | 0.55x | $37.82 Million |
| Sam-A Pharm. Co. Ltd (009300) | $148.92 Billion | 6.63% | 0.09x | $21.27 Million |
| Kyung Dong Pharmaceutical Co. Ltd (011040) | $257.20 Billion | 4.73% | 0.21x | $50.06 Million |
| WooGene B&G Co. Ltd (018620) | $26.51 Billion | -25.02% | 1.26x | $10.61 Million |
| Oscotec Inc (039200) | $28.83 Billion | -91.10% | 0.70x | $890.75 Million |
| EstechPharma Co. Ltd (041910) | $123.30 Billion | 5.58% | 0.09x | $50.99 Million |
| Komipharm International Co. Ltd (041960) | $93.39 Billion | -15.32% | 0.50x | $237.27 Million |
| Eagle Veterinary Technology Co.Ltd (044960) | $40.83 Billion | 8.91% | 0.29x | $20.48 Million |